Association Between hsa-miR-30e Polymorphisms and Sporadic Primary Hyperparathyroidism Risk

Area of Science:

• Endocrinology and Molecular Biology
• Genetics and Genomics
• Oncology

Background:

• Sporadic primary hyperparathyroidism (sPHPT) affects nearly 15% of patients with multiple gland disease (MGD).
• Understanding the genetic and molecular underpinnings of sPHPT, particularly MGD, is crucial for diagnosis and treatment.
• The role of microRNAs, such as hsa-miR-30e, in the tumorigenesis of sPHPT requires further investigation.

Purpose of the Study:

• To investigate the potential role of two hsa-miR-30e polymorphisms in the development of sPHPT.
• To explore the association between hsa-miR-30e expression levels and the presence of multiple gland disease in sPHPT patients.
• To evaluate hsa-miR-30e polymorphisms and expression as potential biomarkers for sPHPT and its subtypes.

Main Methods:

• Genotyping of 120 sPHPT patients (77 single adenoma, 43 MGD) and 54 healthy controls using allele-specific PCR for two hsa-miR-30e SNPs (ss178077483 and rs7556088).
• Analysis of hsa-miR-30e expression levels via real-time quantitative reverse transcriptase PCR.
• Statistical comparison of genotype frequencies and miRNA expression between patient groups and controls.

Main Results:

• Hsa-miR-30e expression was significantly elevated in sPHPT patients with MGD compared to those with single adenomas (p=0.0019).
• No significant differences in hsa-miR-30e expression were observed based on specific genotype carrier status.
• Significant differences in genotype frequencies for ss178077483 and rs7556088 were detected between sPHPT patients and healthy controls.

Conclusions:

• Hsa-miR-30e expression levels may serve as a potential biomarker for differentiating multiple gland disease in sPHPT.
• The investigated hsa-miR-30e polymorphisms (ss178077483 and rs7556088) are not suitable biomarkers for the differential diagnosis of MGD.
• Further research is warranted to elucidate the precise role of hsa-miR-30e in sPHPT tumorigenesis and its clinical utility.